BackAnebulo Pharmaceuticals Overview

Anebulo Pharmaceuticals Total Liabilities

Anebulo Pharmaceuticals's total liabilities is $1.5M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$1.49M
69.05% YoYΔ $606847.00 vs prior year quarter

Peer average

Loading

Anebulo Pharmaceuticals Total Liabilities History

Loading

Anebulo Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Anebulo Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Anebulo Pharmaceuticals (ANEB) FAQ

Anebulo Pharmaceuticals posts a total liabilities of $1.5M as of December 2025. That compares with $880K in the prior-year period — up 69.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Anebulo Pharmaceuticals's total liabilities was $880K. The latest reading is $1.5M — a 69.1% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of Anebulo Pharmaceuticals's financial statement story. At $1.5M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ANEB's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Anebulo Pharmaceuticals's other metric pages and overview cover the third.

Judging Anebulo Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $1.5M here, then scan peer and history charts to see if the gap is persistent.